Background:ST-segment elevation myocardial infarction (STEMI) survivors face a
significant residual risk of developing heart failure (HF) owing to maladaptive left ventricular (LV)
remodeling. Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) are established pillars of care for
chronic HF.Methods: This double-blind, placebo-controlled, prospective, randomized, single-center
trial, enrolled 104 patients with confirmed STEMI and randomized them to be treated with either
dapagliflozin (DAPA) 10 mg daily (n=73) or a matching placebo (n=31), in addition to standard guideline
directed therapy. Echocardiographic parameters, including LV Ejection Fraction (LVEF), Global
Longitudinal Strain (GLS), and LV volumes, were assessed. All patients were assessed at the following
time points: baseline (at admission), 30 days, and following 6 months.Results: At the 6-month follow
up, patients treated with DAPA exhibited superior cardiac function, with higher median LVEF (50% vs.
45%, p=0.002) and improved GLS (-12.0% vs. -10.9%, p=0.022). Notably, adverse LV remodeling was
prevented entirely in the dapagliflozin group (0%) relative to 100% in the placebo group (p |
